For example, Rituximab is a mAb which targets CD20+ B-cells and leads to B-cell depletion in MS patients, while TNF-α (tumor necrosis factor-α) inhibitor, Infliximab, is used in Rheumatoid Arthritis (RA) and Crohn’s disease (12). This evidence concerns the gene TNF and myeloid sarcoma.